FDA Accepts Review of RP1 for Advanced Melanoma; Decision Expected August 2026
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development…
06/26/2026
FDA Accepts Review of RP1 for Advanced Melanoma; Decision Expected August 2026
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development…
|
06/23/2026
Insights from the 2026 the American Academy of Dermatology (AAD) Annual Practice Safe Sun Survey
In May 2026 the American Academy of Dermatology (AAD) released results from the annual Practice Safe Sun Survey. The results…
06/09/2026
The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
For anyone living with a history of skin cancer—or working to prevent it—sun protection shouldn’t be just a summer habit. That’s why today’s announcement from the…
|
06/05/2026
Fifth Annual Evening in Memory of Valerie Guild
Scientific conferences are days-long meetings filled with education, data, and updates for physicians, researchers, scientists, and advocates. One of the…
|
06/05/2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Data for darovasertib in combination with crizotinib presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago…
|
06/05/2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Data for anzutresgene autoleucel presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support a future…
|
06/05/2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Early data for imneskibart with aldesleukin presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago support…
|
06/05/2026
Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)
Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago show that an mRNA individualized neoantigen…
|
06/03/2026
Why Are Young People Tanning Again? What a New allure Feature Reveals About Melanoma Prevention Challenges
A recent feature in allure magazine explores a concerning trend: The resurgence of tanning culture among younger generations. The article…
05/29/2026
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies,…
|
Recent Posts
Jun. 26, 2026
FDA Accepts Review of RP1 for Advanced Melanoma; Decision Expected August 2026
Jun. 23, 2026
Insights from the 2026 the American Academy of Dermatology (AAD) Annual Practice Safe Sun Survey
Jun. 09, 2026
The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026